Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 07, 2024 (filed on Jan 09, 2024)Insider Name:Belsky MarcOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:295,000Price:--
-
Jan 07, 2024 (filed on Jan 09, 2024)Insider Name:Mordwinkin Nicholas MichaelOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:275,000Price:--
Filings by filing date
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 17, 2024 (filed on Jan 17, 2024)Insider Name:Schiller Mark C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 07, 2024 (filed on Jan 09, 2024)Insider Name:Belsky MarcOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:295,000Price:--
-
Jan 07, 2024 (filed on Jan 09, 2024)Insider Name:Mordwinkin Nicholas MichaelOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:275,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4000 Shoreline Ct Ste 300 SOUTH SAN FRANCISCO CA 94080-2005 |
Tel: | N/A |
Website: | https://kezarlifesciences.com |
IR: | See website |
Key People | ||
Christopher Kirk Chief Executive Officer, Director | Marc L. Belsky Chief Financial Officer, Secretary | Neel Anand Senior Vice President - Research and Drug Discovery |
Kieron Wesson Senior Vice President - CMC and Supply Chain | Nick Mordwinkin Chief Business Officer |
Business Overview |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types. |
Financial Overview |
For the fiscal year ended 31 December 2023, Kezar Life Sciences Inc revenues increased from $0K to $7M. Net loss increased 49% to $101.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Clinical stage biotechnology segment loss increase of 57% to $111.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.01 to -$1.40. |
Employees: | 58 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $7.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$104.17M as of Dec 31, 2023 |
Net annual income (TTM): | -$101.87M as of Dec 31, 2023 |
Free cash flow (TTM): | -$83.46M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 72,801,359 as of Mar 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |